Host: Jennifer Caudle, DO

Guest: Christopher Baugh , MD

Although 6 million patients visit the Emergency Department every year with chest pain symptoms, less than 4 percent of those visits lead to a diagnosis of acute myocardial infarction.

To address this gap, Dr. Jennifer Caudle is joined by Dr. Christopher Baugh, Vice Chair of Clinical Affairs at Brigham and Women's Hospital and Associate Professor at Harvard Medical School in Boston Massachusetts, who discusses the adoption of Elecsys Troponin T Gen 5 across the system's Emergency Departments.

Host: Jennifer Caudle, DO

Guest: Moti Ramgopal, MD

As a healthcare provider, it can be important to minimize the time between diagnosis and the beginning of therapy for newly diagnosed HIV-1 patients. That’s why infectious disease specialist Dr. Moti Ramgopal explains how SYMTUZA® can help us close the gap between those two crucial points of a HIV-1 care and be a treatment option when rapididly initiating patients.

INDICATION

SYMTUZA® is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults:

• who have no prior antiretroviral treatment history or
• who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B

• Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF) and may occur with discontinuation of SYMTUZA®.

  Action: Monitor hepatic function with both clinical and laboratory follow-up for at least several months in ...

Host: Jennifer Caudle, DO

Guest: Kristin Higgins, MD

Concurrent chemoradiation therapy is the recommended treatment for unresectable Stage III NSCLC patients. Dr. Jennifer Caudle is joined by Dr. Kristin Higgins to discuss advances in radiation that optimize the treatment plan and her best practices to help patients receive a full course of curative-intent treatment.

US-32345 Last Updated 12/19

Host: Jennifer Caudle, DO

Guest: Kristin Higgins, MD

Concurrent chemoradiation therapy is the recommended treatment for unresectable Stage III NSCLC patients. Dr. Jennifer Caudle is joined by Dr. Kristin Higgins to discuss advances in radiation that optimize the treatment plan and her best practices to help patients receive a full course of curative-intent treatment.

US-32345 Last Updated 12/19

Host: Jennifer Caudle, DO

Guest: Alexander Whitley, MD

Guest: Alejandro Calvo, MD

Guest: Kim Rohan, MS APN, AOCN

At the 2019 ASTRO Annual Meeting, radiation oncologist Dr. Alexander Whitley, medical oncologist Dr. Alejandro Calvo, and nurse practitioner Kim Rohan came together to share their experiences working as part of a multidisciplinary team to care for patients with unresectable Stage III non-small cell lung cancer.

US-32360 Last Updated 12/19

Host: Jennifer Caudle, DO

Guest: Alexander Whitley, MD

Guest: Alejandro Calvo, MD

Guest: Kim Rohan, MS APN, AOCN

At the 2019 ASTRO Annual Meeting, radiation oncologist Dr. Alexander Whitley, medical oncologist Dr. Alejandro Calvo, and nurse practitioner Kim Rohan came together to share their experiences working as part of a multidisciplinary team to care for patients with unresectable Stage III non-small cell lung cancer.

US-32360 Last Updated 12/19

Host: Amy Mackey, MD

Guest: Salim Rezaie, MD

Guest: Evan Alexandrou, MD

By reducing time to therapy, eliminating the need for confirmatory chest x-rays, and reducing the costs associated with these procedures, PICC catheter tip positioning and confirmation using electrocardiogram is revolutionizing vascular access device insertion. To learn more about this technology, Dr. Amy Mackey is joined by Drs. Evan Alexandrou and Salim Rezaie, who share how it works, its use with acute CVCs and dialysis catheters placed in the internal jugular and subclavian veins, and more.

Host: Jennifer Caudle, DO

Guest: Frank LoVecchio, DO, MPH, FACEP

The cold weather inevitably brings an increase in flu cases each year, and joining Dr. Jennifer Caudle to unveil the high-risk populations—and how we can treat the members of those vulnerable populations who do get the flu—is Dr. Frank LoVecchio, Professor of Emergency Medicine at the University of Arizona and Principal Investigator for the Infectious Disease Network.

Host: Jennifer Caudle, DO

Guest: Frank LoVecchio, DO, MPH, FACEP

Guest: Casey Lafferty, DO

Due to the high prevalence of influenza each winter, knowing how to treat those most at risk is essential. That's why Dr. Frank LoVecchio and Dr. Casey Lafferty are here to discuss the 2019-2020 flu season activity and patterns, along with preventive tips and treatment options you can provide to your patients.

Host: Jennifer Caudle, DO

Guest: Richard Channick, MD

Please see the full Prescribing Information here.

This program is intended for US healthcare professionals only and is not certified for continuing medical education. Sponsored by the Janssen Pharmaceutical Companies of Johnson & Johnson.

Pulmonary arterial hypertension (PAH) is a progressive disease that falls under the broader category of pulmonary hypertension.1 Newly diagnosed patients with PAH have a poor prognosis and disease progression is inevitable.2-5 Enormous strides have been made over the past two decades in advancing understanding and treatment of the disease.2

Dr. Richard N. Channick, a Professor of Medicine and Director of the Pulmonary Vascular Disease Program at UCLA Medical Center, joins ReachMD host Dr. Jennifer Caudle to discuss data that explore earlier initiation of treatment for patients with PAH.6,7

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
Concomitant use of strong inhibitors of CYP2C8 (eg, gemfibrozil) with UPTRAVI is contraindicated.

WARNINGS AND PRECAUTIONS
Pulmonary Veno-Occlusive Disease (PVOD)
Should signs of pulmonary edema occur, consider the possibility of associated PVOD. If confirmed, discontinue UPTRAVI.

ADVERSE REACTIONS
Adverse reactions more frequent compared to placebo (≥3%) are headache (65% vs 32%), diarrhea (42% vs 18%), jaw pain (26% vs 6%), nausea (33% vs 18%), myalgia (16% vs 6%), vomiting (18% vs ...